End-of-day quote
Thailand S.E.
23:00:00 16/05/2024 BST
|
5-day change
|
1st Jan Change
|
40.25
THB
|
0.00%
|
|
-0.62%
|
0.00%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
22,669
|
31,169
|
44,029
|
40,760
|
35,093
|
35,093
|
-
|
-
|
Enterprise Value (EV)
1 |
22,104
|
30,451
|
41,666
|
38,309
|
35,093
|
31,940
|
31,321
|
31,441
|
P/E ratio
|
19.8
x
|
22.3
x
|
22.6
x
|
18.2
x
|
17.6
x
|
13.9
x
|
13.3
x
|
12.6
x
|
Yield
|
2.77%
|
2.52%
|
2.1%
|
3.44%
|
-
|
4.31%
|
4.61%
|
5.02%
|
Capitalization / Revenue
|
2.03
x
|
2.47
x
|
3.08
x
|
2.6
x
|
2.24
x
|
2.16
x
|
2.07
x
|
1.99
x
|
EV / Revenue
|
1.98
x
|
2.41
x
|
2.91
x
|
2.44
x
|
2.24
x
|
1.97
x
|
1.85
x
|
1.78
x
|
EV / EBITDA
|
13.7
x
|
15.6
x
|
17.2
x
|
13
x
|
11
x
|
9.69
x
|
9.19
x
|
8.69
x
|
EV / FCF
|
22.9
x
|
21.8
x
|
16.2
x
|
22.6
x
|
-
|
13.4
x
|
12.7
x
|
12.1
x
|
FCF Yield
|
4.37%
|
4.58%
|
6.18%
|
4.42%
|
-
|
7.49%
|
7.89%
|
8.29%
|
Price to Book
|
3.67
x
|
4.48
x
|
5.5
x
|
4.64
x
|
-
|
3.47
x
|
3.09
x
|
3.01
x
|
Nbr of stocks (in thousands)
|
871,870
|
871,870
|
871,870
|
871,870
|
871,870
|
871,870
|
-
|
-
|
Reference price
2 |
26.00
|
35.75
|
50.50
|
46.75
|
40.25
|
40.25
|
40.25
|
40.25
|
Announcement Date
|
24/02/20
|
22/02/21
|
23/02/22
|
25/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11,179
|
12,643
|
14,301
|
15,686
|
15,681
|
16,228
|
16,946
|
17,651
|
EBITDA
1 |
1,613
|
1,951
|
2,426
|
2,953
|
3,190
|
3,297
|
3,407
|
3,620
|
EBIT
1 |
1,451
|
1,695
|
2,305
|
2,681
|
2,904
|
3,025
|
3,056
|
3,246
|
Operating Margin
|
12.98%
|
13.41%
|
16.12%
|
17.09%
|
18.52%
|
18.64%
|
18.04%
|
18.39%
|
Earnings before Tax (EBT)
1 |
1,299
|
1,623
|
2,277
|
2,595
|
2,262
|
2,996
|
3,104
|
3,324
|
Net income
1 |
1,139
|
1,393
|
1,947
|
2,242
|
1,993
|
2,527
|
2,608
|
2,793
|
Net margin
|
10.18%
|
11.02%
|
13.61%
|
14.29%
|
12.71%
|
15.57%
|
15.39%
|
15.82%
|
EPS
2 |
1.310
|
1.600
|
2.230
|
2.570
|
2.290
|
2.904
|
3.016
|
3.194
|
Free Cash Flow
1 |
966.6
|
1,395
|
2,575
|
1,692
|
-
|
2,392
|
2,472
|
2,606
|
FCF margin
|
8.65%
|
11.03%
|
18.01%
|
10.79%
|
-
|
14.74%
|
14.58%
|
14.76%
|
FCF Conversion (EBITDA)
|
59.91%
|
71.49%
|
106.16%
|
57.3%
|
-
|
72.55%
|
72.55%
|
71.98%
|
FCF Conversion (Net income)
|
84.9%
|
100.17%
|
132.29%
|
75.49%
|
-
|
94.67%
|
94.75%
|
93.31%
|
Dividend per Share
2 |
0.7200
|
0.9000
|
1.060
|
1.610
|
-
|
1.733
|
1.855
|
2.020
|
Announcement Date
|
24/02/20
|
22/02/21
|
23/02/22
|
25/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
---|
Net sales
1 |
5,710
|
6,865
|
3,311
|
3,820
|
3,930
|
4,052
|
3,884
|
3,728
|
3,992
|
7,720
|
3,803
|
4,158
|
3,733
|
EBITDA
|
815.6
|
1,115
|
587.3
|
791.8
|
669.2
|
-
|
667.7
|
-
|
-
|
1,525
|
-
|
874.3
|
-
|
EBIT
1 |
-
|
-
|
553.3
|
724.9
|
590.2
|
769.5
|
599.6
|
616.1
|
786.5
|
1,385
|
718.1
|
801.1
|
218.7
|
Operating Margin
|
-
|
-
|
16.71%
|
18.98%
|
15.02%
|
18.99%
|
15.44%
|
16.52%
|
19.7%
|
17.94%
|
18.88%
|
19.27%
|
5.86%
|
Earnings before Tax (EBT)
1 |
706.8
|
993
|
547.7
|
716.6
|
631.9
|
778.5
|
467.6
|
526
|
571
|
-
|
633.1
|
531.6
|
548.5
|
Net income
1 |
623.3
|
837.8
|
496.4
|
614
|
569.5
|
658.3
|
399.8
|
453
|
530.9
|
983.9
|
535.5
|
473.2
|
477.6
|
Net margin
|
10.92%
|
12.2%
|
14.99%
|
16.07%
|
14.49%
|
16.24%
|
10.29%
|
12.15%
|
13.3%
|
12.74%
|
14.08%
|
11.38%
|
12.8%
|
EPS
2 |
0.7100
|
0.9600
|
0.5664
|
0.7000
|
0.6500
|
0.7600
|
0.4600
|
0.5200
|
0.6100
|
1.130
|
0.6100
|
0.5500
|
0.5500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/08/20
|
16/08/21
|
23/02/22
|
13/05/22
|
11/08/22
|
14/11/22
|
25/02/23
|
12/05/23
|
11/08/23
|
11/08/23
|
13/11/23
|
22/02/24
|
14/05/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
565
|
718
|
2,363
|
2,451
|
-
|
3,153
|
3,772
|
3,652
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
967
|
1,395
|
2,575
|
1,692
|
-
|
2,392
|
2,472
|
2,606
|
ROE (net income / shareholders' equity)
|
19.1%
|
21.2%
|
26%
|
26.7%
|
-
|
26.8%
|
24.7%
|
25.3%
|
ROA (Net income/ Total Assets)
|
11.3%
|
12.6%
|
15.7%
|
16.1%
|
-
|
17.1%
|
16.5%
|
17.3%
|
Assets
1 |
10,070
|
11,061
|
12,414
|
13,959
|
-
|
14,776
|
15,857
|
16,142
|
Book Value Per Share
2 |
7.080
|
7.980
|
9.180
|
10.10
|
-
|
11.60
|
13.00
|
13.40
|
Cash Flow per Share
2 |
1.720
|
2.330
|
3.040
|
3.420
|
-
|
3.090
|
3.120
|
3.090
|
Capex
1 |
529
|
234
|
151
|
305
|
-
|
330
|
312
|
329
|
Capex / Sales
|
4.73%
|
1.85%
|
1.06%
|
1.94%
|
-
|
2.03%
|
1.84%
|
1.86%
|
Announcement Date
|
24/02/20
|
22/02/21
|
23/02/22
|
25/02/23
|
22/02/24
|
-
|
-
|
-
|
Last Close Price
40.25
THB Average target price
49.31
THB Spread / Average Target +22.52% Consensus |
1st Jan change
|
Capi.
|
---|
| 0.00% | 970M | | +32.09% | 694B | | +29.39% | 593B | | -1.34% | 371B | | +20.34% | 331B | | +7.39% | 290B | | +14.25% | 239B | | -3.03% | 209B | | +10.02% | 209B | | +8.49% | 169B |
Other Pharmaceuticals
|